{"id":537356,"date":"2021-04-07T18:28:01","date_gmt":"2021-04-07T18:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=537356"},"modified":"2021-04-07T18:28:01","modified_gmt":"2021-04-07T18:28:01","slug":"dysmenorrhea-pipeline-assessment-clinical-trial-key-companies-and-emerging-drugs-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/dysmenorrhea-pipeline-assessment-clinical-trial-key-companies-and-emerging-drugs-by-delveinsight_537356.html","title":{"rendered":"Dysmenorrhea Pipeline Assessment, Clinical Trial, Key Companies, And Emerging Drugs by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Dysmenorrhea Pipeline Assessment, Clinical Trial, Key Companies, And Emerging Drugs by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Dysmenorrhea Pipeline Assessment, Clinical Trial, Key Companies, And Emerging Drugs by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Dysmenorrhea Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">&ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dysmenorrhea-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Dysmenorrhea Pipeline<\/a><\/strong><strong> Insight, 2021<\/strong>&rdquo; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Dysmenorrhea Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;<strong>Dysmenorrhea commercial assessment&nbsp;<\/strong>and clinical assessment of the Dysmenorrhea pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\">In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;<strong>Dysmenorrhea collaborations<\/strong>, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:<br \/> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dysmenorrhea-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/dysmenorrhea-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>The dynamics of the&nbsp;Dysmenorrhea market&nbsp;is anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in the R&amp;D activities.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Dysmenorrhea Companies<\/strong><strong>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Takeda<\/li>\n<li>Mochida<\/li>\n<li>AbbVie<\/li>\n<li>ObsEva SA<\/li>\n<li>Fuji Pharma&rsquo;s<\/li>\n<li>Nobelpharma<\/li>\n<li>Nippon Shinyaku<\/li>\n<li>ASKA Pharmaceutical<\/li>\n<li>Myovant Sciences GmbH<\/li>\n<li>Pure Green Pharmaceuticals<\/li>\n<li>Neurosciences Biosciences<\/li>\n<li><strong>And many others.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/dysmenorrhea-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Dysmenorrhea Therapies<\/a><\/strong><strong>&nbsp;covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Pure Femme Tablets<\/li>\n<li>FSN-013<\/li>\n<li>Yselty<\/li>\n<li>Relugolix<\/li>\n<li><strong>And many others.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Dysmenorrhea Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the&nbsp;<strong>treatment of Dysmenorrhea&nbsp;<\/strong>with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Dysmenorrhea treatment.<\/li>\n<li><strong>Dysmenorrhea key companies&nbsp;<\/strong>involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li><strong>Dysmenorrhea Drugs<\/strong>&nbsp;under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the&nbsp;<strong>Dysmenorrhea market<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:<br \/><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dysmenorrhea-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/dysmenorrhea-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;<strong>Dysmenorrhea Pipeline Report<\/strong>&nbsp;provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and<strong>&nbsp;MOA type for Dysmenorrhea&nbsp;<\/strong>across the complete product development cycle, including all clinical and non-clinical stages.<\/li>\n<li>It comprises detailed profiles of&nbsp;<strong>Dysmenorrhea therapeutic products<\/strong>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/li>\n<li>Detailed research and development progress and<strong>&nbsp;clinical trial of Dysmenorrhea<\/strong>, results wherever available, are also included in the pipeline study.<\/li>\n<li>Coverage of dormant and discontinued pipeline projects along with the reasons if available across Dysmenorrhea.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>A better understanding of disease pathogenesis contributing to the development of&nbsp;<strong>novel therapeutics for Dysmenorrhea<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/li>\n<li>In the coming years, the Dysmenorrhea market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/li>\n<li>The companies and academics are working to assess challenges and seek opportunities that could influence&nbsp;<strong>Dysmenorrhea Research &amp; Development<\/strong>. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/li>\n<li>A detailed portfolio of major pharma players who are involved in fueling the&nbsp;<strong>Dysmenorrhea treatment market<\/strong>. Several potential therapies for Dysmenorrhea are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Dysmenorrhea market size in the coming years.&nbsp;&nbsp;<\/li>\n<li>Our in-depth analysis of the&nbsp;<strong>Dysmenorrhea pipeline<\/strong>&nbsp;assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:<br \/> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/dysmenorrhea-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/dysmenorrhea-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Report Introduction<\/li>\n<li>Dysmenorrhea&nbsp;<\/li>\n<li>Dysmenorrhea Current Treatment Patterns<\/li>\n<li>Dysmenorrhea &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Dysmenorrhea Late Stage Products (Phase-III)<\/li>\n<li>Dysmenorrhea Mid Stage Products (Phase-II)<\/li>\n<li>Early Stage Products (Phase-I)<\/li>\n<li>Pre-clinical Products and Discovery Stage Products<\/li>\n<li>Inactive Products<\/li>\n<li>Dormant Products<\/li>\n<li>Dysmenorrhea Discontinued Products<\/li>\n<li>Dysmenorrhea Product Profiles<\/li>\n<li>Dysmenorrhea Key Companies<\/li>\n<li>Dysmenorrhea Key Products<\/li>\n<li>Dormant and Discontinued Products<\/li>\n<li>Dysmenorrhea Unmet Needs<\/li>\n<li>Dysmenorrhea Future Perspectives<\/li>\n<li>Dysmenorrhea Analyst Review&nbsp;&nbsp;<\/li>\n<li>Appendix<\/li>\n<li>Report Methodology<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong><em>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&shy;&shy;&shy;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=dysmenorrhea-pipeline-assessment-clinical-trial-key-companies-and-emerging-drugs-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/dysmenorrhea-pipeline-insight?utm_source=SatPR&#038;utm_medium=pressrelease&#038;utm_campaign=apr\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/dysmenorrhea-pipeline-insight?utm_source=SatPR&#038;utm_medium=pressrelease&#038;utm_campaign=apr<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/dysmenorrhea-pipeline-insight?utm_source=SatPR&#038;utm_medium=pressrelease&#038;utm_campaign=apr\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=dysmenorrhea-pipeline-assessment-clinical-trial-key-companies-and-emerging-drugs-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dysmenorrhea Pipeline &ldquo;Dysmenorrhea Pipeline Insight, 2021&rdquo; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Dysmenorrhea Market.&nbsp; The assessment part of the report embraces in-depth&nbsp;Dysmenorrhea commercial assessment&nbsp;and clinical assessment of the Dysmenorrhea pipeline &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/dysmenorrhea-pipeline-assessment-clinical-trial-key-companies-and-emerging-drugs-by-delveinsight_537356.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-537356","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/537356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=537356"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/537356\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=537356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=537356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=537356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}